Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 10/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384501 | 1.00 | CDK4 (0.39) | CDK4CDK2EGFRERBB2KDR | |
| SCHEMBL17670374 | 0.91 | EGFR (0.48) | EGFRERBB2KDR | |
| SCHEMBL17670296 | 0.89 | EGFR (0.37) | EGFRERBB2KDRLMNAKMT2A | |
| SCHEMBL31030279 | 0.89 | EGFR (0.37) | EGFRERBB2KDRLMNAKMT2A | |
| SCHEMBL17670286 | 0.88 | EGFR (0.46) | EGFRERBB2KDRLMNAKMT2A | |
| SCHEMBL17670210 | 0.86 | KDR (0.37) | EGFRERBB2KDRMKNK2LMNA | |
| SCHEMBL17670390 | 0.86 | KDR (0.41) | EGFRERBB2KDRMKNK2KMT2A | |
| SCHEMBL30385164 | 0.85 | EGFR (0.40) | EGFRERBB2LMNAKMT2AALDH1A1 | |
| SCHEMBL17670266 | 0.85 | MEN1 (0.41) | EGFRERBB2KDRLMNAKMT2A | |
| SCHEMBL30384546 | 0.85 | MEN1 (0.41) | EGFRERBB2KDRLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3929190-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| EP-3604294-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3207035-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2019-11-20 | — | — | EP | disclosed |
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | CDK4 222/4885CDK2 142/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.